First-year sales of GSK's Alli 'underwhelming,' analyst says

Share this article:
First-year sales of GSK's Alli 'underwhelming,' analyst says
First-year sales of GSK's Alli 'underwhelming,' analyst says

Although four million people have tried GlaxoSmithKline's OTC weight loss drug Alli during its first year on the market, preliminary sales figures are “pretty underwhelming,” one analyst tells the Associated Press.

WBB Securities analyst Steve Brozak said in an AP report today that the “underewhelming” sales for Alli may be a result of the agency's marketing campaign, which stresses the user's need to transform eating and exercise habits for the drug to be effective. This year, the company spent an estimated $150 million on Alli marketing.

GlaxoSmithKline consumer health division marketing director, Joe Cadle, told the AP that first-year sales of Alli point to a “healthy business,” one that can be sustained and grown dramatically as new users try the drug.

“We're the only company with an OTC product that helps treat something that affects 140 million people,” Cadle added.

Alli is a lower dose version of Roche's Xenical (orlistat). GSK acquired the OTC rights to the drug from Roche in 2004. At the time of the Alli's launch last year, GSK estimated it would eventually sell between five million and six million kits annually, translating to at least $1.5 billion in annual retail. A 60-capsule kit costs about $50 while a 90-capsule pack costs about $60.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...